SCHEMBL21611981

SCHEMBL21611981

FC(F)(F)c1cc(SCc2nnc(-c3ccc(Cl)cc3)o2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 3/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ NPSR1 Q6W5P4 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ USP2 O75604 2/20 0.44
▸ TSHR P16473 3/20 0.44
▸ PKM P14618 1/20 0.44
▸ TNKS O95271 2/20 0.43
▸ TNKS2 Q9H2K2 2/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ QPCT Q16769 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HTT P42858 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21611992 0.79 CYP1A2 (0.47) SMN1; SMN2NPSR1NPC1RAB9ALMNA
SCHEMBL27218885 0.76 SMN1; SMN2 (0.51) PTGS2SMN1; SMN2NPSR1NPC1RAB9A
SCHEMBL27218896 0.76 SMN1; SMN2 (0.48) PTGS2SMN1; SMN2NPSR1NPC1RAB9A
SCHEMBL21614743 0.75 DAO (0.38) PTGS2SMN1; SMN2NPSR1NPC1RAB9A
SCHEMBL21611942 0.75 PPARD (0.47) SMN1; SMN2NPSR1NPC1RAB9AALDH1A1
SCHEMBL21614761 0.70 KDM1A (0.37) PTGS2SMN1; SMN2NPSR1NPC1RAB9A
SCHEMBL21611969 0.70 PTGS2 (0.36) PTGS2NPSR1NPC1RAB9AALDH1A1
SCHEMBL21611954 0.70 RXRA (0.48) PTGS2KDM4EMAPT
SCHEMBL21614746 0.68 LOXL2 (0.35) SMN1; SMN2NPC1RAB9AALDH1A1HPGD
SCHEMBL21614744 0.68 HDAC1 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 PTGS2 820/4885SMN1; SMN2 4555/4885NPSR1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback